Form 8-K - Current report:
SEC Accession No. 0001641172-25-001060
Filing Date
2025-03-28
Accepted
2025-03-28 09:00:13
Documents
21
Period of Report
2025-03-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40803
2 ex10-1.htm EX-10.1 4631
3 ex10-1_001.jpg GRAPHIC 665755
4 ex10-1_002.jpg GRAPHIC 605685
5 ex10-1_003.jpg GRAPHIC 606215
6 ex10-1_004.jpg GRAPHIC 508238
7 ex10-1_005.jpg GRAPHIC 672576
8 ex10-1_006.jpg GRAPHIC 178986
9 ex10-1_007.jpg GRAPHIC 142438
  Complete submission text file 0001641172-25-001060.txt   4874000

Data Files

Seq Description Document Type Size
10 XBRL SCHEMA FILE ibo-20250324.xsd EX-101.SCH 3033
11 XBRL LABEL FILE ibo-20250324_lab.xml EX-101.LAB 34240
12 XBRL PRESENTATION FILE ibo-20250324_pre.xml EX-101.PRE 24178
23 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3493
Mailing Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084
Business Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084 585 232 1500
IMPACT BIOMEDICAL INC. (Filer) CIK: 0001834105 (see all company filings)

EIN.: 853926944 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42212 | Film No.: 25781756
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)